Skip to Main Content

Paper Details

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.
Clin Infect Dis
20
2021
AIDS, CV, HIV, Human Immunodeficiency Virus, LS7, PCE, PWH, People, atherosclerotic CV disease, cholesterol, glucose, human, human immunodeficiency virus, participants, persons, women
Author NameAffiliation
Pamela S DouglasDuke Clinical Research Institute, Duke University School of Medicine
Carl J FichtenbaumUniversity of Cincinnati
Judith S CurrierUniversity of California at Los Angeles
Judith S CurrierUniversity of California at Los Angeles
Vicente EstradaHospital San Carlos
Ann Marie NavarUniversity of Texas Southwestern Medical Center
Heather J RibaudoCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health
  • 1 - 7

Datasets

Release 1.2